Eye drop study for limbal stem cell deficiency
Part of Eyes & vision clinical trials.
This study tests a new eye drop called CSB-001 for people with limbal stem cell deficiency (LSCD), a condition that damages the cornea. The goal is to see if the drops can help improve the health of the cornea and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of limbal stem cell deficiency (LSCD) affecting the central part of your cornea (the clear front part of your eye).
- If you are using Acthar for inflammation, you must have been on a stable dose for about 8 weeks and not see much improvement from it.
- You do not have any active eye infection (like bacterial, viral, or fungal) in either eye.
- You have not had eye surgery in the last 30 days that is not fully healed, and you do not plan to have eye surgery during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study follows patients with limbal stem cell deficiency (a condition affecting cells at the edge of the cornea that help maintain healthy eye surface) to understand how their vision changes over time. Researchers will track your eye health without giving you new treatment.
This trial tests an eye treatment made from your own cornea surface cells, grown in a lab and put back into the eye. It may help people with limbal stem cell deficiency by improving the health of the eye surface after a cell biopsy.
This trial tests a treatment that uses your own eye cells to repair the surface of the eye. It may help if you have severe damage to the clear front layer of your eye.
This trial tests a new eye drop to see if it can safely and effectively reduce corneal scars. It is for people who have a recent corneal injury (within the last month) that resulted in a scar that affects their vision.
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
This trial tests an eye drop called BRM421 for people with mild to moderate limbal stem cell deficiency, a condition where the eye's surface doesn't heal properly. The goal is to see if this eye drop helps improve the eye's surface and reduce symptoms.
Hear when a new Limbal Stem Cell Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.